布鲁顿酪氨酸激酶(BTK)信号通路与疾病  

Bruton′s tyrosine kinase (BTK)signaling pathway and disease

作　　者：陈潇 龚国清[1] CHEN Xiao;GONG Guoqing(Department of Pharmacology,China Pharmaceutical University,Nanjing 211198,China)

机构地区：[1]中国药科大学药理学研究室,江苏南京211198

出　　处：《药学研究》2020年第3期169-175,共7页Journal of Pharmaceutical Research

摘　　要：布鲁顿酪氨酸激酶(BTK)是B细胞受体(BCR)信号传导的关键组分,并且作为体内B细胞增殖和细胞存活的重要调节剂起作用。本文综述了布鲁顿酪氨酸激酶信号通路的传导过程,包括主要的B细胞受体信号通路与其他通路。布鲁顿酪氨酸激酶基因缺陷会引发免疫缺陷X连锁性丙种球蛋白血症(XLA),而布鲁顿酪氨酸激酶抑制剂如依鲁替尼最近在患有各种B细胞恶性肿瘤的患者的临床研究中显示出令人印象深刻的抗肿瘤活性,在狼疮和类风湿性关节炎的实验动物模型中也观察到一定治疗作用。Bruton′s tyrosine kinase(BTK)is a key component of B cell receptor(BCR)signaling and functions as an important regulator of cell proliferation and cell survival in B cells in vivo.The paper focus on the signaling processes of BTK,both in BCR signaling pathway,which is the major signaling pathway,and the other signaling pathways.BTK-deficient gene would cause immunodeficiency X-linked gamma globulinemia(XLA),while inhibitors of BTK such as Ibrutinib have very recently shown impressive anti-tumor activity in clinical studies in patients with various B cell malignancies,and promising effects of BTK inhibition were also seen in experimental animal models for lupus and rheumatoid arthritis.

关 键 词：布鲁顿酪氨酸激酶 B细胞受体 免疫缺陷X连锁性丙种球蛋白血症(XLA) 依鲁替尼 B细胞恶性肿瘤 自身免疫疾病 

分 类 号：R967[医药卫生—药理学]